Your session is about to expire
← Back to Search
Bremelanotide + RAAS Inhibitors for Diabetic Kidney Disease (BREAKOUT Trial)
BREAKOUT Trial Summary
This trial will look at how an experimental drug, BMT, affects Type II diabetes when combined with other treatments. After 6 months, patients will have a biopsy to see if it worked.
BREAKOUT Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowBREAKOUT Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.BREAKOUT Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have taken bremelanotide in the last year.You have used certain medications like cyclosporine A, adrenocorticotropic hormones, long-term corticosteroids, or cytotoxic agents in the past 3 months.You have been diagnosed with early to advanced stage kidney disease due to diabetes within the past 5 years.You are taking the highest dose of ACE or ARB medication for high blood pressure and your blood pressure is under control.Your kidney function, measured by eGFR, needs to be at least 20ml/min/1.73m^2.You don't have a history of a very slow heart rate or a heart rate less than 50 beats per minute during screening.Your first urine sample in the morning shows a high protein-to-creatinine ratio.You have a positive test for certain antibodies that indicate active lupus, as determined by the study doctor.You have only one working kidney or are currently undergoing dialysis.You have a heart condition that the doctor thinks could be risky for the study.You have a history of certain kidney problems, recent cancer (except for non-melanoma skin cancer), or certain medical conditions related to high blood sugar levels.You have low blood pressure or severe dehydration with noticeable symptoms.You have Type II diabetes that is well managed, with a HgbA1c level below 10%.You have had a slow heart rate in the past or your current heart rate is less than 50 beats per minute.Your body mass index (BMI) is less than 45.You have allergies or negative reactions to AECI, ARB, or Melanocortin peptides.You have tested positive for hepatitis B, hepatitis C, or HIV.You have a history of regular alcohol or drug dependence, except for cannabis.
- Group 1: Subcutaneous Bremelanotide
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this clinical trial actively recruiting participants?
"This clinical trial is currently recruiting participants, as indicated in its listing on clinicaltrials.gov. Initially posted on December 29th 2022 and last updated January 23rd 2023, the study seeks suitable candidates to enroll."
Is the eligibility criteria of this medical examination limited to those over twenty years old?
"As indicated by this trial's eligibility criteria, all participants must be aged between 18 and 80 years old."
Has the FDA approved Subcutaneous Bremelanotide for public use?
"Subcutaneous Bremelanotide's safety is evaluated as a 2, since there are some data points to back its security but none that can vouch for its efficacy."
How many centers are involved in the management of this experiment?
"At this time, 6 sites across the country are enlisting patients for the study. Potential enrollees can select from Decatur, Lawrenceville and Winston-Salem plus an additional six locations to minimize travel needs."
How many individuals have agreed to participate in this experiment?
"In order to successfully launch this clinical trial, 45 qualified patients must participate. These recruits can sign up at either the Decatur or Lawrenceville branches of Georgia Nephrology Research Institute."
Who meets the criteria to join this research endeavor?
"This study requires 45 individuals aged 18 to 80 that are diagnosed with kidney disease, Type II diabetes mellitus (HgbA1c ≤ 12%), BMI ≤45 kg/m^2., Stage I-III diabetic nephropathy confirmed by biopsy within the last 5 years, on a stable dose of oral diabetic agents or insulin injections for 3+ months prior to randomization, and on a stabile maximum tolerated dose of ACE or ARB as primary antihypertensive therapy. The target blood pressure must be less than 140/90 and additional medications used should have neutral effects on urinary proteinuria. Subjects taking mineralocort"
Share this study with friends
Copy Link
Messenger